Monitor upcoming Phase 2 initiation for denifanstat/resmetirom in F4 MASH and regulatory progress of Ascletis' acne NDA in China. The improved cash position and reduced quarterly losses may support valuation stability, but near-term catalysts are mid-to-late 2026.
Price Chart
Executive Summary
Sagimet Biosciences reported financial results for Q4 and full year 2025, highlighting a reduced net loss despite flat R&D spending, while advancing its clinical pipeline. Key developments include completion of a Phase 1 PK trial for denifanstat/resmetirom combination in MASH, with a Phase 2 trial planned for H2 2026, and positive long-term safety data from Ascletis' Phase 3 acne trial supporting an NDA accepted by China's NMPA. The company ended 2025 with $113.1 million in cash.
Key Financial Metrics
Key Facts
- Completed Phase 1 PK trial of denifanstat and resmetirom combination; Phase 2 trial in F4 MASH patients planned for H2 2026
- Ascletis' NDA for denifanstat in acne accepted by China's NMPA following positive 52-week safety and efficacy data
- Net loss for full year 2025 was $51.0 million, improved from $45.6 million in 2024 despite higher R&D spend in prior year
- Cash, cash equivalents, and marketable securities totaled $113.1 million as of December 31, 2025
- First-in-human Phase 1 trial of TVB-3567 (FASN inhibitor for acne) ongoing; Phase 2 trial anticipated in 2026
Financial Impact
Net loss increased slightly to $51.0M in 2025 from $45.6M in 2024, but cash burn slowed due to lower Q4 R&D spend. Cash balance of $113.1M suggests runway into 2027 assuming current burn rate.
Risk Factors
- Clinical development timelines are subject to regulatory consultation and may be delayed
- Revenue generation remains dependent on partner Ascletis in China, introducing execution and commercialization risk
- No revenue-generating products yet; continued reliance on cash reserves and potential future dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253657 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $9.95 $9.58 | ▼ −3.72% | ▼ −3.20% | $10.42 (+4.72%) |
Oct 7, 2026 19d ago | SC 13G | $8.92 $8.93 | ▲ +0.11% | ▼ −0.49% | $10.42 (+16.82%) |
Oct 1, 2026 26d ago | Press Release | $9.14 $9.03 | ▲ +1.20% | ▲ +1.88% | $10.42 (−14.00%) |
Sep 30, 2026 27d ago | Press Release | $9.88 $9.37 | ▲ +5.16% | ▲ +5.34% | $10.42 (−5.47%) |
Sep 30, 2026 27d ago | 8-K | $9.88 $9.37 | ▼ −5.16% | ▼ −5.34% | $10.42 (+5.47%) |
Sep 22, 2026 5w ago | Institutional Cluster | $11.09 $10.42 | ▼ −6.04% | ▼ −5.32% | $10.42 (−6.04%) |
Aug 25, 2026 9w ago | Press Release | $10.29 $10.86 | ▲ +5.54% | ▲ +5.52% | $10.42 (+1.26%) |
Aug 11, 2026 11w ago | 8-K | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $10.42 (+9.45%) |
Aug 11, 2026 11w ago | Press Release | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $10.42 (+9.45%) |
Jul 22, 2026 13w ago | Insider Cluster | $7.01 $7.07 | ▲ +0.86% | ▲ +0.75% | $10.42 (+48.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers